BioBrit — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)Alan Fuhrman(Executive Officer)
BoardRobert More(Director)Nina Kjellson(Director)in
Co-investorsAlta PartnersNextech InvestCanaan Partners
In The Bowl Animal Health (ITBAH) develops and commercializes antiparasitics and therapeutics for pets by incorporating the drug directly into the pet's daily food to improve compliance and convenience.
BiotechConsumerFoodTechHealthtechNashville, US
Randolph Legg(Chief Executive Officer)Scott Holmstrom, Ph.D.(Chief Scientific Officer)Eric Graves(Director)Jay Ferguson(Executive Officer)Robin Readnour(Director)Diane Hirakawa(Director)
Co-investorsMountain Group Capital
Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes.
BiotechHealthtechCarlsbad, US
Kirk Hammond(Director)Shawn Swaney(Executive Officer)
BoardRoy Cosan(Director)Pierre Lecocq(Director)Vijay Mahant(Director)Michael Torres(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.